Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression

[1]  O. Elemento,et al.  Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma , 2019, Gynecologic oncology reports.

[2]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[3]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Kurzrock,et al.  HER2 aberrations in cancer: implications for therapy. , 2014, Cancer treatment reviews.

[5]  M. Stoler,et al.  HER2 Immunohistochemistry Significantly Overestimates HER2 Amplification in Uterine Papillary Serous Carcinomas , 2014, The American journal of surgical pathology.

[6]  A. Santin,et al.  HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. , 2014, Archives of pathology & laboratory medicine.

[7]  M. Davy,et al.  Serous carcinoma of the uterus—determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation , 2007, International Journal of Gynecologic Cancer.

[8]  N. Sneige,et al.  Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  John D. Olson,et al.  College of American Pathologists , 2020, Definitions.